- Home
- NATR vs CLLS Comparison
NATR vs CLLS Comparison
Compare NATR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NATR
- CLLS
- Stock Information
- Founded
- NATR 1972
- CLLS 1999
- Country
- NATR United States
- CLLS France
- Employees
- NATR N/A
- CLLS N/A
- Industry
- NATR Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NATR Health Care
- CLLS Health Care
- Exchange
- NATR Nasdaq
- CLLS Nasdaq
- Market Cap
- NATR 254.1M
- CLLS 240.2M
- IPO Year
- NATR N/A
- CLLS 2007
- Fundamental
- Price
- NATR $13.16
- CLLS $1.97
- Analyst Decision
- NATR Strong Buy
- CLLS Buy
- Analyst Count
- NATR 2
- CLLS 2
- Target Price
- NATR $19.50
- CLLS $8.00
- AVG Volume (30 Days)
- NATR 32.7K
- CLLS 22.5K
- Earning Date
- NATR 11-05-2024
- CLLS 11-04-2024
- Dividend Yield
- NATR N/A
- CLLS N/A
- EPS Growth
- NATR 191.23
- CLLS N/A
- EPS
- NATR 0.79
- CLLS N/A
- Revenue
- NATR $441,682,000.00
- CLLS $19,635,000.00
- Revenue This Year
- NATR $0.59
- CLLS $271.02
- Revenue Next Year
- NATR $4.12
- CLLS $33.48
- P/E Ratio
- NATR $16.58
- CLLS N/A
- Revenue Growth
- NATR 2.14
- CLLS N/A
- 52 Week Low
- NATR $10.81
- CLLS $0.96
- 52 Week High
- NATR $21.72
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- NATR 44.34
- CLLS 37.13
- Support Level
- NATR $12.97
- CLLS $1.88
- Resistance Level
- NATR $14.18
- CLLS $2.08
- Average True Range (ATR)
- NATR 0.41
- CLLS 0.12
- MACD
- NATR -0.02
- CLLS -0.04
- Stochastic Oscillator
- NATR 15.70
- CLLS 17.31
About NATR Nature's Sunshine Products Inc.
Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.